reproxalap
Small moleculeexperimental
Clinical trial activity
17 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
16
Phase 3
10
Phase 4
0
Earliest trial started Jan 2, 2018 (NCT03404115)
Timeline
Indications
Mechanism of action
- CD63 antigenINHIBITOR
CD63 inhibitor
- Unspecified targetOTHER
Reactive aldehyde species (RASP) inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(O)c1nc2ccc(Cl)cc2cc1N- Mol. weight
- 236.7 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297210 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06493604 | Phase 3 | Jun 24, 2024 | Aldeyra Therapeutics, Inc. |
| NCT06424444 | Phase 3 | Apr 29, 2024 | Aldeyra Therapeutics, Inc. |
| NCT06389214 | Phase 3 | Apr 9, 2024 | Aldeyra Therapeutics, Inc., Cliantha Research Limited |
| NCT05424549 | Phase 2 | Mar 9, 2022 | Aldeyra Therapeutics, Inc. |
| NCT05234554 | Phase 3 | Jan 21, 2022 | Aldeyra Therapeutics, Inc. |
| NCT05102409 | Phase 2 | Sep 9, 2021 | Aldeyra Therapeutics, Inc. |
| NCT05062330 | Phase 3 | Aug 28, 2021 | Aldeyra Therapeutics, Inc. |
| NCT04971031 | Phase 2 | Jun 15, 2021 | Aldeyra Therapeutics, Inc. |
| NCT04735393 | Phase 3 | Jan 26, 2021 | Aldeyra Therapeutics, Inc. |
| NCT04674358 | Phase 2/Phase 3 (Phase 3) | Nov 21, 2020 | Aldeyra Therapeutics, Inc. |
| NCT04207736 | Phase 3 | Dec 5, 2019 | Aldeyra Therapeutics, Inc. |
| NCT03916042 | Phase 2 | Apr 23, 2019 | Aldeyra Therapeutics, Inc. |
| NCT03879863 | Phase 3 | Apr 1, 2019 | Aldeyra Therapeutics, Inc. |
| NCT03709121 | Phase 1/Phase 2 (Phase 2) | Oct 2, 2018 | Aldeyra Therapeutics, Inc. |
| NCT03660878 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2018 | Aldeyra Therapeutics, Inc. |
| NCT03494504 | Phase 3 | Mar 30, 2018 | Aldeyra Therapeutics, Inc. |
| NCT03404115 | Phase 2 | Jan 2, 2018 | Aldeyra Therapeutics, Inc. |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aldeyra Therapeutics, Inc. | For profit | 17 | 17 | 2 | 2018 |
| Cliantha Research Limited | For profit | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1